^
    Back
    Association details:
    Biomarker:RAD51AP1 overexpression
    Cancer:Hepatocellular Cancer
    Drug:Targretin oral (bexarotene oral) (Retinoid X receptor modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int J Gen Med
    Title:

    RAD51AP1 as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma

    Published date:
    09/26/2023
    Excerpt:
    ...whereas Bexarotene, Doxorubicin, Gemcitabine and Tipifarnib had lower IC50s, which suggested that the HCC patients with high-RAD51AP1 expression may be more susceptible to the treatment Bexarotene, Doxorubicin, Gemcitabine and Tipifarnib (all P < 0.05, Figure 11).
    DOI:
    https://doi.org/10.2147/IJGM.S431206